Wall Street brokerages predict that NeoGenomics, Inc. (NASDAQ:NEO) will report $0.05 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for NeoGenomics’ earnings, with the lowest EPS estimate coming in at $0.04 and the highest estimate coming in at $0.08. NeoGenomics also reported earnings per share of $0.05 in the same quarter last year. The business is scheduled to report its next quarterly earnings results on Wednesday, February 20th.

On average, analysts expect that NeoGenomics will report full year earnings of $0.18 per share for the current year, with EPS estimates ranging from $0.15 to $0.19. For the next year, analysts forecast that the firm will post earnings of $0.24 per share, with EPS estimates ranging from $0.22 to $0.28. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for NeoGenomics.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 30th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $69.10 million for the quarter, compared to analyst estimates of $66.13 million. NeoGenomics had a return on equity of 2.63% and a net margin of 1.70%. The business’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.01 earnings per share.

Several brokerages have recently commented on NEO. Benchmark set a $22.00 price target on NeoGenomics and gave the company a “buy” rating in a research note on Thursday, November 1st. Craig Hallum raised their price target on NeoGenomics from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, October 31st. Raymond James raised their price target on NeoGenomics from $16.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, October 31st. Zacks Investment Research upgraded NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research note on Saturday, November 3rd. Finally, BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 27th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and three have issued a strong buy rating to the company. NeoGenomics presently has an average rating of “Buy” and a consensus target price of $20.00.

Shares of NeoGenomics stock traded up $0.01 during trading on Thursday, hitting $16.01. 484,859 shares of the stock traded hands, compared to its average volume of 532,387. The firm has a market cap of $1.55 billion, a P/E ratio of 266.83 and a beta of -0.01. The company has a current ratio of 4.13, a quick ratio of 3.98 and a debt-to-equity ratio of 0.32. NeoGenomics has a 52-week low of $7.08 and a 52-week high of $19.04.

In related news, major shareholder Electric Co General sold 4,164,855 shares of the firm’s stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $16.75, for a total transaction of $69,761,321.25. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Jennifer Balliet sold 39,828 shares of the firm’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $17.00, for a total value of $677,076.00. Following the sale, the vice president now directly owns 55,000 shares in the company, valued at approximately $935,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,976,643 shares of company stock worth $83,483,198. 12.20% of the stock is owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. WINTON GROUP Ltd boosted its holdings in NeoGenomics by 23.5% in the third quarter. WINTON GROUP Ltd now owns 25,530 shares of the medical research company’s stock worth $392,000 after acquiring an additional 4,866 shares in the last quarter. American International Group Inc. boosted its holdings in NeoGenomics by 15.5% in the third quarter. American International Group Inc. now owns 42,114 shares of the medical research company’s stock worth $646,000 after acquiring an additional 5,652 shares in the last quarter. Jennison Associates LLC boosted its holdings in NeoGenomics by 18.7% in the second quarter. Jennison Associates LLC now owns 43,736 shares of the medical research company’s stock worth $573,000 after acquiring an additional 6,888 shares in the last quarter. Cornerstone Wealth Management LLC acquired a new stake in NeoGenomics in the second quarter worth about $528,000. Finally, Glenmede Trust Co. NA acquired a new stake in NeoGenomics in the third quarter worth about $114,000. 82.37% of the stock is currently owned by institutional investors.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Recommended Story: What is the quiet period?

Get a free copy of the Zacks research report on NeoGenomics (NEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.